Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Docetaxel Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 4/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 4/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 4/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 4/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 4/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 4/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 4/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 4/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 4/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 4/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 4/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 4/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 4/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 4/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Docetaxel Anhydrous SCHEMBL19236131 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL13524298 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL177909 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL22503340 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL25052982 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL12127070 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL25446250 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL21465719 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL23134940 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL22667521 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144838-A1 | THERANOSTIC SYSTEM FOR DIRECTED DIFFUSION OF THERAPEUTIC AND IMAGING AGENTS TO CANCER CELLS | UNIVERSITAT POLITÈCNICA DE VALÈNCIA (ES) | 2023-05-11 | — | — | US | disclosed |
| WO-2023053054-A1 | PROCESS FOR THE PREPARATION OF TAXANE DERIVATIVES | INDENA S.P.A. (IT) | 2023-04-06 | — | — | WO | disclosed |
| EP-2288340-B1 | NANOPARTICLE FORMULATIONS AND USES THEREOF | ABRAXIS BIOSCIENCE LLC (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-2416650-B1 | NANOPARTICLE FORMULATIONS AND USES THEROF | ABRAXIS BIOSCIENCE LLC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10406239-B2 | Water-soluble docetaxel anticancer drug compound and preparation method and use thereof | NANJING YOUYI MEDICAL TECHNOLOGY CO., LTD (CN) | 2019-09-10 | — | — | US | disclosed |
| US-9944752-B2 | Block copolymers for stable micelles | INTEZYNE TECHNOLOGIES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9889206-B2 | C-Met targeting compound-bioactive material conjugate and use thereof | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2018-02-13 | — | — | US | disclosed |
| US-20170253699-A1 | BLOCK COPOLYMERS FOR STABLE MICELLES | INTEZYNE TECHNOLOGIES, INC. | 2017-09-07 | — | — | US | disclosed |
| US-20170172975-A1 | NANOPARTICLE FORMULATIONS AND USES THEREOF | ABRAXIS BIOSCIENCE, LLC | 2017-06-22 | — | — | US | disclosed |
| US-20170056510-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-02 | — | — | US | disclosed |
| US-7615653-B2 | Anti-tuberculosis taxane compounds | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090263483-A1 | NANOPARTICLE FORMULATIONS AND USES THEREOF | ABRAXIS BIOSCIENCE, LLC | 2009-10-22 | — | — | US | disclosed |
| US-20090263483-A1 | NANOPARTICLE FORMULATIONS AND USES THEREOF | ABRAXIS BIOSCIENCE, LLC | 2009-10-22 | — | — | US | disclosed |
| WO-2009126938-A1 | NANOPARTICLE FORMULATIONS AND USES THEREOF | ABRAXIS BIOSCIENCES, LLC (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009126175-A1 | COMPOSITIONS OF HYDROPHOBIC TAXANE DERIVATIVES AND USES THEREOF | ABRAXIS BIOSCIENCE, LLC (US) | 2009-10-15 | — | — | WO | disclosed |
| US-7550608-B2 | Processes for the preparation of docetaxel | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20090137796-A1 | METHODS FOR THE PREPARATION OF TAXANES USING CHIRAL AUXILIARIES | BIOXEL PHARMA INC. (CA) | 2009-05-28 | — | — | US | disclosed |
| US-20090062376-A1 | Preparation of Taxanes From 9-Dihydro-13-Acetylbaccatin III | BIOXEL PHARMA INC. (CA) | 2009-03-05 | — | — | US | disclosed |
| US-20080081836-A1 | Anti-Tuberculosis Taxane Compounds | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2008-04-03 | — | — | US | disclosed |
| US-20080081836-A1 | Anti-Tuberculosis Taxane Compounds | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062376-A1 | Preparation of Taxanes From 9-Dihydro-13-Acetylbaccatin III | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SIRT3, PARP9 | TUBB4A 116/4885TUBB 75/4885TUBA3C 25/4885 |
| US-20080081836-A1 | Anti-Tuberculosis Taxane Compounds | TUBB, TOP2A, TUBB1 | TUBB4A 12/4885TUBB 1/4885TUBA3C 38/4885 |
| US-20090263483-A1 | NANOPARTICLE FORMULATIONS AND USES THEREOF | ABCB1, SLC47A1, ABCC1 | TUBB4A 612/4885TUBB 548/4885TUBA3C 312/4885 |
| US-20170172975-A1 | NANOPARTICLE FORMULATIONS AND USES THEREOF | ABCB1, SLC47A1, ABCC1 | TUBB4A 612/4885TUBB 548/4885TUBA3C 312/4885 |
| US-20230144838-A1 | THERANOSTIC SYSTEM FOR DIRECTED DIFFUSION OF THERAPEUTIC AND IMAGING AGENTS TO CANCER CELLS | FOLR1, EGFR, FOLR2 | TUBB4A 959/4885TUBB 878/4885TUBA3C 1592/4885 |
| US-20090137796-A1 | METHODS FOR THE PREPARATION OF TAXANES USING CHIRAL AUXILIARIES | TOP2B, TOP1, TOP2A | TUBB4A 21/4885TUBB 6/4885TUBA3C 30/4885 |
| US-20170056510-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | TUBB4A 828/4885TUBB 501/4885TUBA3C 152/4885 |
| US-10406239-B2 | Water-soluble docetaxel anticancer drug compound and preparation method and use thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DHCR7, CCR7 | TUBB4A 119/4885TUBB 68/4885TUBA3C 8/4885 |
| US-20170253699-A1 | BLOCK COPOLYMERS FOR STABLE MICELLES | ABCB4, CLTB, EPHA2 | TUBB4A 88/4885TUBB 47/4885TUBA3C 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.